In vitro effects of recombinant activated factor VII on thrombin generation and coagulation following inhibition of platelet procoagulant activity by prasugrel

Thrombosis Research

Volumn 132, Issue 1, 2013, Pages 106-111

  Mazzeffi, Michael ^a,b,c   Szlam, Fania ^a,b,c   Jakubowski, Joseph A ^a,b,c   Tanaka, Kenichi A ^a,b,c   Sugidachi, Atsuhiro ^a,b,c   Levy, Jerrold H ^a,b,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c DAIICHI SANKYO CO   (Japan)

Author keywords

Anti platelet drugs; Bleeding; Prasugrel; rFVIIa

Indexed keywords

ADENOSINE DIPHOSPHATE; COLLAGEN; DRUG METABOLITE; PRASUGREL; R 138727; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD CLOTTING TIME; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; THROMBIN TIME; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA; THROMBOELASTOGRAPHY;

ANTI-PLATELET DRUGS; BLEEDING; PRASUGREL; RFVIIA;

ADULT; AGED; BLOOD COAGULATION; BLOOD PLATELETS; FACTOR VIIA; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECOMBINANT PROTEINS; THIOPHENES; THROMBELASTOGRAPHY; THROMBIN; YOUNG ADULT;

EID: 84881316904     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.04.007     Document Type: Article

References (20)

1. J.A. Jakubowski, K.J. Winters, H. Naganuma, and L. Wallentin Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile Cardiovasc Drug Rev 25 2007 357 374 (Pubitemid 350233359)
2. S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, and S. Gottlieb Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015 (Pubitemid 350106708)
3. K.U. Petersen Relevance of metabolic activation pathways: the example of clopidogrel and prasugrel Arzneimittelforschung 59 2009 213 227
4. F. Szlam, K.A. Tanaka, B. Rumph, D. Bolliger, and J.H. Levy In vitro effects of recombinant activated factor VIIa (NovoSeven) on clopidogrel-induced platelet inhibition Thromb Haemost 103 2010 863 865
5. R. Altman, A. Scazziota, Herrera M. De Lourdes, and C. Gonzalez Recombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generation J Thromb Haemost 4 2006 2022 2027 (Pubitemid 44226784)
6. J. Kawasaki, N. Katori, T. Taketomi, K. Terui, and K.A. Tanaka The effects of vasoactive agents, platelet agonists and anticoagulation on thrombelastography Acta Anaesthesiol Scand 51 2007 1237 1244 (Pubitemid 47389697)
7. V. Bewick, L. Cheek, and J. Ball Statistics review 10: further nonparametric methods Crit Care 8 2004 196 199 (Pubitemid 38735700)
8. P. Barash, and S. Akhtar Coronary stents: factors contributing to perioperative major adverse cardiovascular events Br J Anaesth 105 Suppl. 1 2010 i3 i15
9. M.U. Zafar, C. Santos-Gallego, D.A. Vorchheimer, J.F. Viles-Gonzalez, S. Elmariah, and C. Giannarelli Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementation J Thromb Haemost 11 2013 100 106
10. H.M. Judge, R.J. Buckland, A. Sugidachi, J.A. Jakubowski, and R.F. Storey Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function Thromb Haemost 103 2010 1210 1217
11. A.L. Frelinger III, J.A. Jakubowski, Y. Li, M.R. Barnard, M.D. Linden, and I. Tarnow The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities J Thromb Haemost 6 2008 359 365
12. J.P. Herault, F. Dol, C. Gaich, A. Bernat, and J.M. Herbert Effect of clopidogrel on thrombin generation in platelet-rich plasma in the rat Thromb Haemost 81 1999 957 960 (Pubitemid 29312715)
13. P.A. Gurbel, K.P. Bliden, K. Guyer, N. Aggarwal, and U.S. Tantry Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting Thromb Res 119 2007 563 570 (Pubitemid 46321504)
14. K. Vanschoonbeek, M.A. Feijge, R.J. Van Kampen, H. Kenis, H.C. Hemker, and P.L. Giesen Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristics J Thromb Haemost 2 2004 476 484 (Pubitemid 40185661)
15. K.G. Mann, K. Brummel-Ziedins, A. Undas, and S. Butenas Does the genotype predict the phenotype? Evaluations of the hemostatic proteome J Thromb Haemost 2 2004 1727 1734 (Pubitemid 40192713)
16. W.T. Sumner, D.M. Monroe, and M. Hoffman Variability in platelet procoagulant activity in healthy volunteers Thromb Res 81 1996 533 543
17. G. Scharbert, A. Auer, and S. Kozek-Langenecker Evaluation of the Platelet Mapping Assay on rotational thromboelastometry ROTEM Platelets 20 2009 125 130
18. K.A. Tanaka, F. Szlam, A.B. Kelly, J.D. Vega, and J.H. Levy Clopidogrel (Plavix) and cardiac surgical patients: implications for platelet function monitoring and postoperative bleeding Platelets 15 2004 325 332 (Pubitemid 39037135)
19. M. Levi, J.H. Levy, H.F. Andersen, and D. Truloff Safety of recombinant activated factor VII in randomized clinical trials N Engl J Med 363 2010 1791 1800
20. K. Karkouti, and J.H. Levy Commentary: recombinant activated factor VII: the controversial conundrum regarding its off-label use Anesth Analg 113 2011 711 712